From promise to pitfalls: immunological lessons from dengue vaccines and their implications
Cassia F. Estofolete, Marielena V. Saivish, Maurício L. Nogueira, Nikos Vasilakis
TL;DR
This paper reviews the challenges in developing effective dengue vaccines, focusing on immune responses and safety issues.
Contribution
The paper provides a critical evaluation of immunological factors affecting dengue vaccine development and offers insights for future strategies.
Findings
Licensed dengue vaccines show serostatus-dependent safety and protection issues.
Serotype imbalance and cross-reactivity complicate vaccine efficacy.
Vector-mediated immune modulation and orthoflavivirus interactions remain key obstacles.
Abstract
Dengue continues to pose a significant global health threat. However, the development of a safe and effective tetravalent vaccine is impeded by complex serotype-specific and cross-reactive immune responses. This review assesses licensed and advanced dengue vaccines, emphasizing serostatus-dependent safety, serotype imbalance, and the durability of protection. It also critically evaluates immunological correlates of protection and addresses remaining obstacles, such as vector-mediated immune modulation and orthoflavivirus cross-reactivity, to guide future dengue vaccine strategies.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsMosquito-borne diseases and control · Viral Infections and Outbreaks Research · Parasitic Diseases Research and Treatment